Research programme: cytokine inhibitors - RottapharmAlternative Names: CR 3719
Latest Information Update: 25 Feb 2010
At a glance
- Originator Rottapharm
- Mechanism of Action Cytokine inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 22 Mar 2007 Preclinical trials in Neuropathic pain in Italy (unspecified route)
- 22 Mar 2007 Preclinical trials in Osteoarthritis in USA (unspecified route)